MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

被引:380
作者
Huang, Sidong [1 ,2 ]
Hoelzel, Michael [1 ,2 ]
Knijnenburg, Theo [1 ,2 ]
Schlicker, Andreas [1 ,2 ]
Roepman, Paul [4 ,5 ]
McDermott, Ultan [6 ]
Garnett, Mathew [6 ]
Grernrum, Wipawadee [1 ,2 ]
Sun, Chong [1 ,2 ]
Prahallad, Anirudh [1 ,2 ]
Groenendijk, Floris H. [1 ,2 ]
Mittempergher, Lorenza [1 ,2 ]
Nijkamp, Wouter [1 ,2 ]
Neefjes, Jacques [3 ]
Salazar, Ramon [7 ]
ten Dijke, Peter [8 ]
Uramoto, Hidetaka [9 ]
Tanaka, Fumihiro [9 ]
Beijersbergen, Roderick L. [1 ,2 ]
Wessels, Lodewyk F. A. [1 ,2 ]
Bernards, Rene [1 ,2 ,4 ,5 ]
机构
[1] Netherlands Canc Inst, Canc Genom Ctr, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Canc Syst Biol Ctr, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands
[4] Agendia Inc, Irvine, CA 92618 USA
[5] Agendia NV, NL-1098 XH Amsterdam, Netherlands
[6] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England
[7] Inst Catala Oncol IDIBELL, Lhospitalet De Llobregat 08908, Spain
[8] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands
[9] Univ Occupat & Environm Hlth, Dept Surg 2, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
基金
欧洲研究理事会;
关键词
ANAPLASTIC LYMPHOMA KINASE; CELL LUNG-CANCER; COLORECTAL-CANCER; RESISTANCE; MUTATIONS; SENSITIVITY; INHIBITION; PATHWAY; THERAPY; SCREEN;
D O I
10.1016/j.cell.2012.10.035
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibitors of the ALK and EGF receptor tyrosine kinases provoke dramatic but short-lived responses in lung cancers harboring EML4-ALK translocations or activating mutations of EGFR, respectively. We used a large-scale RNAi screen to identify MED12, a component of the transcriptional MEDIATOR complex that is mutated in cancers, as a determinant of response to ALK and EGFR inhibitors. MED12 is in part cytoplasmic where it negatively regulates TGF-beta R2 through physical interaction. MED12 suppression therefore results in activation of TGF-beta R signaling, which is both necessary and sufficient for drug resistance. TGF-beta signaling causes MEK/ERK activation, and consequently MED12 suppression also confers resistance to MEK and BRAF inhibitors in other cancers. MED12 loss induces an EMT-like phenotype, which is associated with chemotherapy resistance in colon cancer patients and to gefitinib in lung cancer. Inhibition of TGF-beta R signaling restores drug responsiveness in MED12(KD) cells, suggesting a strategy to treat drug-resistant tumors that have lost MED12.
引用
收藏
页码:937 / 950
页数:14
相关论文
共 31 条
[11]   Systematic identification of genomic markers of drug sensitivity in cancer cells [J].
Garnett, Mathew J. ;
Edelman, Elena J. ;
Heidorn, Sonja J. ;
Greenman, Chris D. ;
Dastur, Anahita ;
Lau, King Wai ;
Greninger, Patricia ;
Thompson, I. Richard ;
Luo, Xi ;
Soares, Jorge ;
Liu, Qingsong ;
Iorio, Francesco ;
Surdez, Didier ;
Chen, Li ;
Milano, Randy J. ;
Bignell, Graham R. ;
Tam, Ah T. ;
Davies, Helen ;
Stevenson, Jesse A. ;
Barthorpe, Syd ;
Lutz, Stephen R. ;
Kogera, Fiona ;
Lawrence, Karl ;
McLaren-Douglas, Anne ;
Mitropoulos, Xeni ;
Mironenko, Tatiana ;
Thi, Helen ;
Richardson, Laura ;
Zhou, Wenjun ;
Jewitt, Frances ;
Zhang, Tinghu ;
O'Brien, Patrick ;
Boisvert, Jessica L. ;
Price, Stacey ;
Hur, Wooyoung ;
Yang, Wanjuan ;
Deng, Xianming ;
Butler, Adam ;
Choi, Hwan Geun ;
Chang, JaeWon ;
Baselga, Jose ;
Stamenkovic, Ivan ;
Engelman, Jeffrey A. ;
Sharma, Sreenath V. ;
Delattre, Olivier ;
Saez-Rodriguez, Julio ;
Gray, Nathanael S. ;
Settleman, Jeffrey ;
Futreal, P. Andrew ;
Haber, Daniel A. .
NATURE, 2012, 483 (7391) :570-U87
[12]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[13]   ZNF423 Is Critically Required for Retinoic Acid-induced Differentiation and Is a Marker of Neuroblastoma Outcome [J].
Huang, Sidong ;
Laoukili, Jamila ;
Epping, Mirjam T. ;
Koster, Jan ;
Holzel, Michael ;
Westerman, Bart A. ;
Nijkamp, Wouter ;
Hata, Akiko ;
Asgharzadeh, Shahab ;
Seeger, Robert C. ;
Versteeg, Rogier ;
Beijersbergen, Roderick L. ;
Bernards, Rene .
CANCER CELL, 2009, 15 (04) :328-340
[14]   COT drives resistance to RAF inhibition through MAP kinase pathway reactivation [J].
Johannessen, Cory M. ;
Boehm, Jesse S. ;
Kim, So Young ;
Thomas, Sapana R. ;
Wardwell, Leslie ;
Johnson, Laura A. ;
Emery, Caroline M. ;
Stransky, Nicolas ;
Cogdill, Alexandria P. ;
Barretina, Jordi ;
Caponigro, Giordano ;
Hieronymus, Haley ;
Murray, Ryan R. ;
Salehi-Ashtiani, Kourosh ;
Hill, David E. ;
Vidal, Marc ;
Zhao, Jean J. ;
Yang, Xiaoping ;
Alkan, Ozan ;
Kim, Sungjoon ;
Harris, Jennifer L. ;
Wilson, Christopher J. ;
Myer, Vic E. ;
Finan, Peter M. ;
Root, David E. ;
Roberts, Thomas M. ;
Golub, Todd ;
Flaherty, Keith T. ;
Dummer, Reinhard ;
Weber, Barbara L. ;
Sellers, William R. ;
Schlegel, Robert ;
Wargo, Jennifer A. ;
Hahn, William C. ;
Garraway, Levi A. .
NATURE, 2010, 468 (7326) :968-U370
[15]   K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[16]   TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor [J].
Kim, Young-Woong ;
Park, Jinah ;
Lee, Hyun-Ju ;
Lee, So-Young ;
Kim, Seong-Jin .
BIOCHEMICAL JOURNAL, 2012, 445 :403-411
[17]   Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer [J].
Kwak, Eunice L. ;
Bang, Yung-Jue ;
Camidge, D. Ross ;
Shaw, Alice T. ;
Solomon, Benjamin ;
Maki, Robert G. ;
Ou, Sai-Hong I. ;
Dezube, Bruce J. ;
Jaenne, Pasi A. ;
Costa, Daniel B. ;
Varella-Garcia, Marileila ;
Kim, Woo-Ho ;
Lynch, Thomas J. ;
Fidias, Panos ;
Stubbs, Hannah ;
Engelman, Jeffrey A. ;
Sequist, Lecia V. ;
Tan, WeiWei ;
Gandhi, Leena ;
Mino-Kenudson, Mari ;
Wei, Greg C. ;
Shreeve, S. Martin ;
Ratain, Mark J. ;
Settleman, Jeffrey ;
Christensen, James G. ;
Haber, Daniel A. ;
Wilner, Keith ;
Salgia, Ravi ;
Shapiro, Geoffrey I. ;
Clark, Jeffrey W. ;
Iafrate, A. John .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1693-1703
[18]   EMT is the dominant program in human colon cancer [J].
Loboda, Andre ;
Nebozhyn, Michael V. ;
Watters, James W. ;
Buser, Carolyne A. ;
Shaw, Peter Martin ;
Huang, Pearl S. ;
Van't Veer, Laura ;
Tollenaar, Rob A. E. M. ;
Jackson, David B. ;
Agrawal, Deepak ;
Dai, Hongyue ;
Yeatman, Timothy J. .
BMC MEDICAL GENOMICS, 2011, 4
[19]   Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].
Maemondo, Makoto ;
Inoue, Akira ;
Kobayashi, Kunihiko ;
Sugawara, Shunichi ;
Oizumi, Satoshi ;
Isobe, Hiroshi ;
Gemma, Akihiko ;
Harada, Masao ;
Yoshizawa, Hirohisa ;
Kinoshita, Ichiro ;
Fujita, Yuka ;
Okinaga, Shoji ;
Hirano, Haruto ;
Yoshimori, Kozo ;
Harada, Toshiyuki ;
Ogura, Takashi ;
Ando, Masahiro ;
Miyazawa, Hitoshi ;
Tanaka, Tomoaki ;
Saijo, Yasuo ;
Hagiwara, Koichi ;
Morita, Satoshi ;
Nukiwa, Toshihiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388
[20]   MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas [J].
Makinen, Netta ;
Mehine, Miika ;
Tolvanen, Jaana ;
Kaasinen, Eevi ;
Li, Yilong ;
Lehtonen, Heli J. ;
Gentile, Massimiliano ;
Yan, Jian ;
Enge, Martin ;
Taipale, Minna ;
Aavikko, Mervi ;
Katainen, Riku ;
Virolainen, Elina ;
Bohling, Tom ;
Koski, Taru A. ;
Launonen, Virpi ;
Sjoberg, Jari ;
Taipale, Jussi ;
Vahteristo, Pia ;
Aaltonen, Lauri A. .
SCIENCE, 2011, 334 (6053) :252-255